Tango Therapeutics, Inc. (TNGX) Stock Quote & Options Analysis | Frenzy Capital
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- 52-Week Range
- $1.03 – $28.41
- YTD
- +210.97%
- IV Rank (30D)
- 100
- Straddle Price
- $7.32
- P/C Vol Ratio
- 0.50
- Market Cap
- $3.8B
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNAS
- Market Cap
- $3.8B
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | +3.30% | 5 |
| Feb | -8.85% | 5 |
| Mar | -1.42% | 5 |
| Apr | +7.29% | 5 |
| May | +9.20% | 4 |
| Jun | +28.10% | 4 |
| Jul | +6.63% | 4 |
| Aug | +29.28% | 5 |
| Sep | +7.63% | 5 |
| Oct | +12.96% | 5 |
| Nov | -4.08% | 5 |
| Dec | -0.56% | 5 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 78.5 | Overbought |
| MACD | 2.498 | Bullish |
| SMA 50 | $17.62 | Above |
| SMA 200 | $10.69 | Above |
| Bollinger Bands | Overbought | |
| ADX | 58.4 | Strong Trend |
| HV 30 | 64.6% |
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
| Published | Title | Publisher | Sentiment |
|---|---|---|---|
| 2026-03-19 | The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology | GlobeNewswire Inc. | |
| 2026-03-06 | Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | GlobeNewswire Inc. | |
| 2026-03-04 | Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing | The Motley Fool | |
| 2026-01-05 | Tango Therapeutics Appoints Sung Lee to Board of Directors | GlobeNewswire Inc. | |
| 2025-08-26 | Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference | GlobeNewswire Inc. | |
| 2025-08-06 | Tango (TNGX) Q2 Revenue Drops 52% | The Motley Fool | |
| 2025-06-27 | Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines’ Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer | GlobeNewswire Inc. | |
| 2025-05-27 | Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference | GlobeNewswire Inc. |
- IV Rank (30D)
- 100
- IV Rank (7D)
- 100
- Avg IV
- 240.9%
- Straddle (30D)
- $7.32
- Straddle (7D)
- $7.32
- P/C Volume
- 0.50
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Enter a ticker to render the implied volatility surface.
- Beta (1Y vs SPY)
- 1.70
- Correlation (SPY)
- 20.0%
- R²
- 0.04
- Ann. Volatility
- 109.7%
- SPY Volatility
- 12.9%
High volatility - stock moves more than market
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
| P/B Ratio | 11.0 |
| P/S Ratio | 61.0 |
| EV/EBITDA | -33.9 |
| ROE | -29.3% |